 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
 |
 |
|
MONOCLONAL
ANTIBODIES AS ANTI-
|
|
|
TYROSINE KINASE RECEPTOR
DRUGS
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
Anti-RTK mAbs
block the
|
|
ligand-receptor
interaction
|
|
|
ð inhibition of ligand-induced
|
|
RTK signaling
|
|
|
ð increase of RTK down
|
|
regulation and
internalization
|
|
|
|
|
|
Zwick et al, Trends in
Molecular Medicine (2002) 8: 17-23
|
|
|
|
|
|